By Jonathan Stempel NEW YORK, July 21 (Reuters) - Amgen reached a $74 million settlement of a lawsuit accusing the ...

Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the public. | Amgen has agreed to a $74 million settlement with investors to ...

Earlier in July, a federal judge blocked Colorado’s plan to impose a 70% price cap on Amgen’s blockbuster arthritis drug Enbrel, halting a significant state-level pricing move. The ruling eased ...

A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen (AMGN) and is refocusing attention on the stock’s earnings setup. See our ...

Colorado is one of a handful of states with a review board for drug prices and one of only four with a board empowered to set ...

Tests found that the foreign matter does not pose a clinical risk to patients.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s rare-disease drug, citing concerns ...

Amgen will employ the Veeva Clinical Platform to support and identify efficiencies across the clinical trial process. "We're excited to help Amgen further advance clinical development. Veeva Clinical ...

Amgen said there is no link between its experimental weight loss drug, MariTide, and changes in bone density. The statement comes a day after that potential safety concern wiped off more than $12 ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...